Maastricht Science Programme, Faculty of Science and Engineering, Maastricht University, Paul-Henri Spaaklaan, 1, PO Box 616, 6200 MD, Maastricht, the Netherlands.
Maastricht Science Programme, Faculty of Science and Engineering, Maastricht University, Paul-Henri Spaaklaan, 1, PO Box 616, 6200 MD, Maastricht, the Netherlands.
Eur J Med Chem. 2021 Nov 5;223:113651. doi: 10.1016/j.ejmech.2021.113651. Epub 2021 Jun 22.
Given the increasing reports of well-defined bimetallic molecular complexes as potential anticancer agents in the last decades, along with the prevalence of platinum in anticancer therapy, we report here a detailed survey of bimetallic platinum and palladium complexes investigated as potential anticancer agents. Specifically, we will concentrate on the synthesis, characterisation and biological (anticancer) studies of a sub-class of these agents, namely homo and heterobimetallic complexes bearing a bridging phosphane ligand of the type: [LM(μ-RP(CH)PR)ML] (where M is platinum or palladium, M is any other transition metal, R = alkyl or aryl substituents, L or L are co-ligands, n = 1-6). We will review the in vitro and in vivo activities and any mechanistic anticancer studies of these complexes with a view of trying to delineate patterns in biological activity and structure-activity relationships (SAR). We do not include the review of bimetallic complexes in this class that have not undergone any anticancer testing, nor those that have been involved in other biological investigations unrelated to cancer studies.
鉴于近几十年来越来越多关于明确的双金属分子配合物作为潜在抗癌剂的报道，以及铂在抗癌治疗中的广泛应用，我们在此报告了对作为潜在抗癌剂研究的双金属铂和钯配合物的详细调查。具体来说，我们将集中研究这些药物的一个子类的合成、表征和生物学（抗癌）研究，即具有桥连膦配体[LM(μ-RP(CH)PR)ML]的同核和异核双金属配合物（其中 M 是铂或钯，M 是任何其他过渡金属，R = 烷基或芳基取代基，L 或 L 是共配体，n = 1-6）。我们将回顾这些配合物的体外和体内活性以及任何抗癌机制研究，以期尝试描绘生物活性和构效关系（SAR）的模式。我们不包括未经过任何抗癌测试的此类双金属配合物的综述，也不包括那些已参与与癌症研究无关的其他生物学研究的双金属配合物。
